General form of registration statement for all companies including face-amount certificate companies

JANUARY AND MARCH 2012 FINANCING (Details Textual)

v2.4.0.6
JANUARY AND MARCH 2012 FINANCING (Details Textual) (USD $)
12 Months Ended 67 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2012
Debt Conversion, Converted Instrument, Shares Issued (in shares)   3,985,000  
Entity's Volume Weighted Average Price $ 1.73    
Warrants Exercise Terms and Expiration Description In the event that the Company's average daily volume weighted average price was at or above $0.75 during the Measuring Period, the Class B Warrants were to expire unexercised. The Announcement Date was the earlier of (1) the date on which the Company announces via press release the results of the pharmacokinetic study of its TNX-102 drug formulation; or (2) June 1, 2012. On April 5, 2012 the Company issued a press release announcing the results of the pharmacokinetic study of its TNX-102 drug formulation, which is defined as an Announcement Date for the purpose of the Class B Warrants. Based on the Company's average daily volume weighted average price, which was $1.73 per share, during the Measuring Period, the Class B Warrants expired unexercised.    
Change in fair value of warrant liability $ 1,177,026 $ 0 $ 1,177,026
Warrants Issued During Period To Purchase Common Stock 30,750    
Percentage Of Shares Issuable Upon Excercise Of Warrants   33.00%  
Warrants reclassified to equity upon expiry of reset provisions 3,938,946 0 3,938,946
Warrants Exercise Price (in dollars per share) $ 1.00    
Debt Instrument, Convertible, Beneficial Conversion Feature 710,000    
Common Stock [Member]
     
Number Of Shares Included In One Stock Unit (in shares) 25,000    
Warrant [Member]
     
Valuation Assumptions Issuance Date 1 Jan. 20, 2012    
Valuation Assumptions Issuance Date 2 Mar. 01, 2012    
Valuation Assumptions Expiration Date Jun. 06, 2012    
Additional Paid-In Capital [Member]
     
Warrants reclassified to equity upon expiry of reset provisions 3,938,946    
Placement Agents [Member]
     
Financing Arrangements Expense 706,511    
Warrants Exercise Price (in dollars per share) $ 1.00    
Placement Agents [Member] | Other Financing Cost [Member]
     
Financing Arrangements Expense 270,798    
Placement Agents [Member] | Additional Paid-In Capital [Member]
     
Financing Arrangements Expense 435,713    
Minimum [Member]
     
Percentage Of Investor Fee Payable Under Registration Rights Agreement 1.00%    
Maximum [Member]
     
Percentage Of Investor Fee Payable Under Registration Rights Agreement 10.00%    
Class A Warrant [Member]
     
Number Of Warrants Included In One Stock Unit 1    
Debt Conversion, Converted Instrument, Shares Issued (in shares) 25,000    
Warrants Exercise Period 5 years    
Class B Warrant [Member]
     
Number Of Warrants Included In One Stock Unit 1    
Debt Conversion, Converted Instrument, Shares Issued (in shares) 25,000    
Entity Minimum Volume Weighted Average Price Effect On Exercise Warrants $ 0.75    
January 2012 Financing [Member]
     
Stock Units Issued During Period 172.118    
Proceeds From Issuance Of Stock Units 2,377,950    
Proceeds From Conversion Of Convertible Debentures 1,925,000    
Warrants Issued During Period To Purchase Common Stock 4,302,950    
Stock Units Issued Upon Conversion Of Convertible Debt Purchase Price 25,000    
January 2012 Financing [Member] | Placement Agents [Member]
     
Warrants Issued During Period To Purchase Common Stock 235,295    
March 2012 Financing [Member]
     
Stock Units Issued During Period 92.5926    
Warrants Issued During Period To Purchase Common Stock 2,314,815    
March 2012 Financing [Member] | Placement Agents [Member]
     
Warrants Issued During Period To Purchase Common Stock 231,482    
Financing Arrangements [Member]
     
Warrants Exercise Period 7 years    
Percentage Of Shares Issuable Upon Excercise Of Warrants 10.00%    
Warrants Exercise Price (in dollars per share) $ 1.25    
Financing Arrangements [Member] | Placement Agents [Member]
     
Payment For Commission 466,777    
Percentage Of Commission Paid 8.00%    
Percentage Of Non Accountable Expenses 2.00%    
Warrants Issued During Period To Purchase Common Stock 466,777    
Financing Arrangements [Member] | Class A Warrant [Member]
     
Warrants Not Settleable In Cash Fair Value Disclosure 2,549,684   2,549,684
Warrants Exercise Price (in dollars per share) $ 1.25    
Financing Arrangements [Member] | Agent Warrants [Member]
     
Warrants Not Settleable In Cash Fair Value Disclosure 212,235   212,235
December 2012 Financing [Member]
     
Stock Units Issued During Period 6,404,167    
Proceeds From Issuance Of Stock Units 1,615,000    
December 2012 Financing [Member] | Convertible Debentures Converted To Units [Member]
     
Debt Conversion Converted Instrument Discount Price Percentage 25.00%    
Debt Instrument, Convertible, Beneficial Conversion Feature 236,667    
December 2012 Financing [Member] | Placement Agents [Member]
     
Stock Units Issued During Period 2,500,000    
Proceeds From Issuance Of Stock Units 1,000,000    
Payment For Commission $ 70,000    
Percentage Of Commission Paid 7.00%    
December 2012 Financing [Member] | Minimum [Member]
     
Percentage Of Investor Fee Payable Under Registration Rights Agreement 1.00%    
December 2012 Financing [Member] | Maximum [Member]
     
Percentage Of Investor Fee Payable Under Registration Rights Agreement 10.00%    
December 2012 Financing [Member] | Class A Warrant [Member]
     
Number Of Warrants Included In One Stock Unit 1    
Warrants Exercise Period 5 years    
Warrants Exercise Price (in dollars per share) $ 0.6    
December 2012 Financing [Member] | Class B Warrant [Member]
     
Number Of Warrants Included In One Stock Unit 1    
Warrants Exercise Period 1 year    
Warrants Exercise Price (in dollars per share) $ 0.4